Cipla to remain unfazed by Trump's protectionist policy
Saturday, March 4, 2017, 6:58 PM
Umang Vohra global CEO of Cipla said, US President Donald Trump's protectionist policies are unlikely to affect the company's US business. US is a very important market for Cipla and almost 80 percent of the drugs sold by Cipla in the US market, are manufactured in US itself. "We will increase manufacturing capabilities in the US if needed," Vohra said.